Metabolites as immunomodulatory additives for biomaterials

Información del proyecto

Met4Bone

Identificador del acuerdo de subvención: 898858

DOI

10.3030/898858

Proyecto cerrado

Fecha de la firma de la CE 28 Abril 2020

Fecha de inicio 1 Agosto 2020

Fecha de finalización 31 Julio 2022

Financiado con arreglo a

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Coste total

€ 152 202,24

Aportación de la UE

€ 152 202,24

Coordinado por

RIGAS TEHNISKA UNIVERSITATE
Latvia

Periodic Reporting for period 1 - Met4Bone (Metabolites as immunomodulatory additives for biomaterials)

Período documentado: 2020-08-01 hasta 2022-07-31

Resumen del contexto y de los objetivos generales del proyecto

Biomaterials are widely used for the surgical remediation of various bone defects. However, there are still several risks associated with this treatment. The project's main goal was to develop novel biomaterials for bone regeneration with incorporated endogenous metabolites with immune regulatory properties. We applied a conceptually new approach for biomaterial development where metabolites are incorporated in biomaterials ensuring local delivery of endogenous small molecules to control cell functions. Our ambition is that fundamental knowledge and novel biomaterials generated during this project will result in new therapeutic strategies to improve the recovery of patients suffering from bone fractures.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

Several LC-MS and GC-FID-based methods were established for analyzing metabolites in biological samples. The in vivo experiments were carried out to characterize the systemic alterations in the metabolite profile during bone healing. Based on the obtained results, an amino acid was identified that could be incorporated into biomaterials to promote bone tissue regeneration. Furthermore, we comprehensively characterize calcium phosphate-based biomaterials' influence on cell metabolism. The project's results have been presented at four conferences and contributed to the publication of three manuscripts. Moreover, project aims, goals, results, and MSCA were promoted in more than 20 different dissemination and outreach activities aimed at different target audiences, including researchers, students, policymakers, and school kids.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

The results of the MSCA-IF project significantly contributed to the emerging field of immunomodulatory biomaterials development. We have characterized the systemic metabolism changes during bone healing and identified potential endogenous metabolites that could be incorporated into biomaterials to promote bone regeneration. Furthermore, for the first time, we have comprehensively characterized calcium phosphate-based biomaterials' influence on cell metabolism. The gained knowledge can be used for the metabolomics-driven design of biomaterials and to develop a new in vitro screening platform for biomaterials by combining in vitro cell culture models and mass spectrometry-based metabolomics readout. The project's most important socio-economic benefit would be improved bone disease patients' management and quality of life and reduced health care costs. Even though due to the fundamental nature, the project does not result in an immediate benefit for the patients, we anticipate that in a 5-10 year time frame, the result obtained in this project will lead to novel clinical treatment procedures for bone fractures. Based on preliminary and literature data, our conservative estimate is that such therapy will result in at least a 10% reduction in healing time. Considering the average bone fracture healing time of 6-8 weeks, it would result in at least 6 days' faster recovery.

Met4Bone project graphical summary